Welcome to the Autumn 2021 edition of Haavind’s Pharma Report. Pharma Report is a retrospective, report on legal developments in Norway relevant for the pharmaceutical sector, covering topics both within regulatory affairs and intellectual property. The report has been published twice a year since 2016.
In the Autumn 2021 edition, we take a closer look on the recently implemented legislation to allow for interchangeability on biological medicines. You can also read about the new regime on administrative sanctions for violations of certain aspects of pharmaceutical law. In addition, you can read about a patent case concerning a melatonin formulation, as well as a pharmaceutical company’s attempt to challenge the amendment from non-prescription to prescription status for a popular medicinal product.
Haavind’s Health and Life Science team continuously and closely monitors developments in Norway relevant to the pharma sector. If you wish to discuss how your business can best meet the legal challenges of this innovative and highly regulated sector, you are always welcome to contact us.